Aktienanalyse zu Harrow Inc (HROW)HROWHarrow Inc

Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in the United States, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, FLAREX, NATACYN, BYQLOVI and others. Its development-stage programs include MELT-300, H-N08, CR-01, and MELT-210. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Harrow Inc. is currently not a strong buy due to its low RSI of 29.596, indicating oversold conditions, and a significant year-to-date decline of 25.33%. However, the potential upside is notable with analyst price targets averaging around $65, suggesting a possible 74% increase from the current price of $37.27. The main risk is the high forward P/E ratio of 263.16, indicating that the stock may be overvalued based on future earnings expectations.